Special Committee of ProFrac Holding Corp.’s Board of Directors in the all-stock acquisition of U.S. Well Services, Inc.
Colgate Energy Partners III LLC in its $3.9 billion merger of equals with Centennial Resource Development Inc. (NASDAQ: CDEV) to create the largest pure-play E&P in the Delaware Basin
Polestar Performance AB in its $20 billion combination with Gores Guggenheim Inc.
KKR and Atlantic Aviation in the merger of Atlantic Aviation and Ross Aviation
Celanese Corporation in its $11 billion acquisition of a majority of DuPont’s Mobility & Materials Business
Macquarie Infrastructure Partners in its acquisition of GreenWaste Recovery and Zanker Road Resource Management
Indigo Natural Resources LLC in its $2.7 billion merger with Southwestern Energy Company
Carlisle Companies in its $1.575 billion acquisition of Henry Company
K+S Aktiengesellschaft in its $3.2 billion sale of its Americas salt business (including Morton Salt) to Stone Canyon Industries Holdings, Mark Demetree and affiliates
Tokio Marine in its $3.1 billion acquisition of Privilege Underwriters and PURE Group
Harris Corporation in its $35 billion merger of equals with L3 Technologies to form L3Harris Technologies
L3Harris Technologies in its $350 million divestiture of the Harris night vision business to Elbit Systems of America
Praxair in its $80 billion merger of equals with Linde AG
Amazon.com in its $13.7 billion acquisition of Whole Foods
Ontario Teachers' Pension Plan in its equity partnership with IFM Investors and British Columbia Investment Management in GCT Global Container Terminals
Sempra Energy in its activist campaign defense and cooperation agreement with Elliott Management and Bluescape Energy Partners
Stemcentrx in its $9.8 billion acquisition by AbbVie
BHP in its $10.8 billion sale of its interests in the Eagle Ford, Haynesville, Permian and Fayetteville Onshore US oil and gas assets to BP and Merit Energy Company
Abrams Capital Management in the sale of Netrality Data Centers to Macquarie Infrastructure Partners IV
Biohaven in its sale of $150 million of royalty rights and common stock to Royalty Pharma
* Certain matters were prior to joining Kirkland.